V Secukinumab Safety Study for Giant Cell Arteritis or Polymyalgia Rheumatica

This open-label studyexamined how a medication called secukinumab behaves in the body when given through an IV infusion (directly into a vein) in adults with Giant Cell Arteritis (GCA)

Duration

~ 6 months

Visits

6 – 8 clinic visits

Compensation

Yes, Provided

Location

Bellevue, WA

About This Trial

This open-label study (meaning all participants knew which treatment they received) examined how a medication called secukinumab behaves in the body when given through an IV infusion (directly into a vein) in adults with Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR).

Researchers looked at how quickly the drug is absorbed and cleared, as well as its safety and tolerability. Secukinumab is already approved for other conditions; this study tested a different way of delivering it.

Condition: Giant Cell Arteritis / Polymyalgia Rheumatica

Learn more: View on ClinicalTrials.gov

Check Your Eligibility Screening

Answer a few questions to see if you may qualify for our gout clinical trial.

Eligibility screening is not available at the moment.

This is completely confidential, your answers are processed locally and are not stored or transmitted. Only your contact information is saved if you choose to submit it.

Other Trials

We have several clinical trials and you may be eligible for more than one. Lets find out.

V Secukinumab Safety Study for Giant Cell Arteritis or Polymyalgia Rheumatica

This open-label studyexamined how a medication called secukinumab behaves in the body when given through an IV infusion (directly into a vein) in adults with Giant Cell Arteritis (GCA)

About This Trial

Check Your Eligibility Screening

Other Trials

Evaluating Sarilumab for Adults with Early Polymyalgia Rheumatica (PMR)

Testing Natrunix Combined with Methotrexate for Rheumatoid Arthritis

Using a Molecular Test to Guide Treatment Choice for Rheumatoid Arthritis

Continued Secukinumab Treatment for Prior Novartis Study Participants

Testing a New Combination Treatment for Gout

Testing a New Treatment (LY3871801) for Moderate-to-Severe Rheumatoid Arthritis

Blood Sample Study for Rheumatoid Arthritis Patients Starting a New Medication

AR882 for Gout Patients Who Have Not Responded to Prior Uricase Therapy

Testing LY2439821 for Moderate-to-Severe Plaque Psoriasis

Testing Nipocalimab for Moderate-to-Severe Sjögren’s Disease

Testing Afimetoran for Active Lupus (SLE)

Phase 3 Study of AR882 for Gout